Literature DB >> 8324151

Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.

E J Goldstein1.   

Abstract

The activity of the fluoroquinolone antibiotics against anaerobic bacteria has generally been moderate to poor. Nalidixic acid and cinoxacin show poor activity against almost all anaerobes. Norfloxacin and enoxacin exhibit poor anaerobic activity (MIC90, 8- > 256 micrograms/mL) except against Clostridium perfringens, Bacteroides ureolyticus, and some eubacteria. Norfloxacin is slightly more active than enoxacin against some Bacteroides species. While ciprofloxacin is more active than earlier fluoroquinolones against anaerobes such as Bacteroides fragilis (MIC90, 4-16 micrograms/mL), fusobacteria, and peptostreptococci, its activity is often variable and its MIC90 is frequently close to the maximal level attainable in serum. Ofloxacin is active against B. fragilis (MIC90, 4-8 micrograms/mL) but not against other species of the B. fragilis group (MIC90, 8-32 micrograms/mL); other anaerobes (e.g., peptostreptococci and fusobacteria) are generally susceptible to < or = 8 micrograms of ofloxacin/mL. Several newer quinolones exhibit improved anaerobic activity (although the studies yielding relevant data have often used diverse methods, small numbers and varieties of isolates, and different breakpoints). CI-960 and WIN 57273 inhibit 95% of strains tested at < or = 2 micrograms/mL. CI-990, sparfloxacin, and temafloxacin inhibit most anaerobes at < or = 2 micrograms/mL, but clustering around the breakpoint and strain variability have been noted. CI-990 is active against more than 85% of B. fragilis strains (MIC90, 4 micrograms/mL), but other species of the B. fragilis group often require > 4 micrograms/mL for inhibition; Prevotella bivia, Fusobacterium varium, and Fusobacterium ulcerans are usually resistant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324151     DOI: 10.1093/clinids/16.supplement_4.s377

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Arthroplastic and osteosynthetic infections due to Propionibacterium acnes: a retrospective study of 52 cases, 1995-2002.

Authors:  M-F Lutz; P Berthelot; A Fresard; C Cazorla; A Carricajo; A-C Vautrin; M-H Fessy; F Lucht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

2.  Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

Authors:  K E Aldridge; D S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  Are incidence and epidemiology of anaerobic bacteremia really changing?

Authors:  A Vena; P Muñoz; L Alcalá; A Fernandez-Cruz; C Sanchez; M Valerio; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-28       Impact factor: 3.267

4.  Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.

Authors:  J Mättö; S Asikainen; M L Väisänen; B Von Troil-Lindén; E Könönen; M Saarela; K Salminen; S M Finegold; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  In vitro activity of new quinolones against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Accumulation of norfloxacin by Bacteroides fragilis.

Authors:  V Ricci; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 7.  Gram-positive anaerobic cocci.

Authors:  D A Murdoch
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Authors:  M L Peterson; L B Hovde; D H Wright; A D Hoang; J K Raddatz; P J Boysen; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.

Authors:  M A Smith; P Alperstein; K France; E M Vellozzi; H D Isenberg
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.